Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Predictive role of absolute ly...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma

Show other versions (1)
Bibliographic Details
Main Authors: Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Format: Article
Language:English
Published: The Korean Association of Internal Medicine 2023-07-01
Series:The Korean Journal of Internal Medicine
Online Access:http://kjim.org/upload/kjim-2022-183e.pdf
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

http://kjim.org/upload/kjim-2022-183e.pdf

Similar Items

  • Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
    by: Hee Jeong Cho, et al.
    Published: (2023-03-01)
  • Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
    by: Ja Min Byun, et al.
    Published: (2022-10-01)
  • Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
    by: Ga-Young Song, et al.
    Published: (2023-10-01)
  • Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
    by: Hee-Jeong Cho, et al.
    Published: (2018-06-01)
  • Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study
    by: Ji Hyun Lee, et al.
    Published: (2024-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs